v3.25.3
EARNINGS PER SHARE (EPS)
6 Months Ended
Sep. 30, 2025
EARNINGS PER SHARE (EPS)  
EARNINGS PER SHARE (EPS)

NOTE 5 – EARNINGS PER SHARE (EPS)

Basic EPS is computed by dividing reported earnings available to stockholders by the weighted average number of shares outstanding. Diluted EPS also includes the effect of stock options and restricted stock that would be dilutive. The following table provides a reconciliation of the numerators and denominators reflected in the basic and diluted earnings per share computations for the periods indicated:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three Months ended

    

Three Months ended

     

Six Months ended

     

Six Months ended

​

​

​

September 30, 2025

​

September 30, 2024

​

September 30, 2025

​

September 30, 2024

​

Basic and diluted EPS

​

​

​

​

​

​

​

​

​

​

​

​

​

Net income (loss)

​

$

825

​

$

(601)

​

$

228

​

$

(2,061)

​

Net income (loss) per share – basic and diluted

​

$

0.08

​

$

(0.06)

​

$

0.02

​

$

(0.22)

​

Weighted average shares – basic

​

 

9,874,627

​

​

9,568,660

​

​

9,816,556

​

​

9,279,967

​

Dilutive effect of stock options

​

​

280,938

​

​

—

​

​

212,611

​

​

—

​

Weighted average shares – diluted

​

​

10,155,565

​

​

9,568,660

​

​

10,029,167

​

​

9,279,967

​

​

​

The following table depicts all potential common stock equivalents that have an anti-dilutive effect were excluded from the calculation of diluted EPS (i.e., those that increase income per share or decrease loss per share), for the periods indicated:

​

​

​

​

​

​

​

​

​

​

​

    

Three Months ended

    

Three Months ended

    

Six Months ended

    

Six Months ended

​

​

September 30, 2025

​

September 30, 2024

​

September 30, 2025

​

September 30, 2024

Stock options

 

—

​

542,500

 

—

 

542,500

Warrants

 

711,083

 

566,783

 

711,083

 

566,783

Restricted stock

 

5,000

 

10,000

 

5,000

 

10,000

​

From time to time, we may enter into contracts that are indexed to and settled in our own stock, such as warrants. Contracts that require settlement in shares are equity instruments and measured at fair value. Subsequent changes in fair value are not recognized if the contracts continue to be classified as equity. In connection with the sale of our common stock and warrants to purchase shares of our common stock in fiscal 2025 in a private placement, we recorded the sale of common stock and warrants as shareholder’s equity at a combined purchase price of $3.46. The portion of the proceeds received for the stock and warrant that are allocable to the warrant was accounted for as additional paid-in-capital. The allocation was based on the relative fair market values of the two securities at the time of issuance.